about
Panic disorder and incident coronary heart disease: a systematic review and meta-analysis protocolA Review of the External Validity of Clinical Trials with Beta-Blockers in Heart FailurePerhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial.Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adultsComparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications.Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.Aging of the nitric oxide system: are we as old as our NO?Tachycardic vs. pharmacologic stress myocardial perfusion imaging: differential implications in multi-vessel ischemia.Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation.Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED scoreAortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk.Cardiovascular Health in Anxiety or Mood Problems Study (CHAMPS): study protocol for a randomized controlled trialPlatelet Reactivity Is Independent of Left Atrial Wall Deformation in Patients with Atrial Fibrillation.Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillationInterplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome.Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond.Modulation of myocardial metabolism: an emerging therapeutic principle.Prevention of aortic valve stenosis: a realistic therapeutic target?Clopidogrel "resistance": pre- vs post-receptor determinants.Brain natriuretic peptide: a biomarker for all cardiac disease?Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy.Pharmacology and therapeutic role of inorganic nitrite and nitrate in vasodilatation.Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes.Aging of platelet nitric oxide signaling: pathogenesis, clinical implications, and therapeutics.Early use of N-Acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial).Seasonal variation in AF-related admissions to a coronary care unit in a "hot" climate: fact or fiction?Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events.Composite outcome measures in a pragmatic clinical trial of chronic heart failure management: A comparative assessment.New-onset atrial fibrillation and thromboembolic risk: Cardiovascular syzygy?A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS.Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines.Emerging drugs for the treatment of angina pectoris.Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial.Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia.
P50
Q24288843-D1D4D50F-4EB0-47BD-AE64-AABEE6C2D818Q28068618-50A10015-A76D-4BD6-8F0A-6683ABDCCE8AQ33589769-22FEF4E1-8754-497F-89FD-6FC83EE9133CQ33657136-2611AB89-48BB-42D8-8932-77E97D502264Q33882750-CB7CC239-C520-4140-9A4B-93DCF0929639Q34532327-977CE59A-22E7-45F0-99F7-79A57CDC1B3EQ34583579-FAAF2241-448E-4C41-9E7E-08E0284E06B4Q35026305-97DA2E53-1119-40D0-B30D-B79F587295CAQ35669598-43100109-4FF0-49B4-AFF6-01E5D2388032Q35669612-C42D6B2C-A1C4-45D2-B695-4439D98179D4Q35826004-314A7CE4-78E4-4242-B7A1-4760FB88BD81Q35962795-26338019-D7FE-4F27-80EE-09E7B26A9BA9Q36083677-F9B3EB95-2399-4828-B94D-0CD8F2B7FD03Q36449508-F13981CD-B672-4931-BA07-039AD137B66EQ36741772-93224663-C3EF-41C6-8A87-3E8E11A65617Q36784683-09417194-7BC8-4DB5-89B0-EEB91DA51669Q37176809-A69AFA6A-5248-4064-B36F-D87ED0C86AC9Q37590495-A7A7444E-B515-47CD-BE03-214D8839A010Q37763834-B00633FF-8269-4F47-9131-145A19478788Q38003816-6A66E7EC-1F38-41C4-BA73-FDC9ED60B86DQ38154064-2ED449E1-BAFF-4BA5-9BE9-ECE7BA51D58AQ38177086-03769F8D-333B-488F-875A-73923BDFA397Q38210281-503D1058-D291-4B1D-841A-C2BAB91D380CQ38225938-D9BFA62E-44D5-45D0-8174-5A56E10F4992Q38236593-3764DBE5-4585-45EE-BF79-C084856B2A15Q38244839-22C8EC06-909F-461D-AB53-A741BDF2C607Q38375235-E59A5866-AE17-4F3F-882E-E073014333DAQ38479432-E38F7CF7-DC40-4C39-A712-EEE39263BFAAQ38509269-B795854C-B884-46E4-8AD7-BDC565BC062DQ38562262-4A47DDB0-7C5B-455F-8097-CBCB2D38ACCCQ38675261-C4807FB8-8B71-4C6F-8D6A-1EA3FA9F77D2Q38801662-01810376-4D50-4688-A027-1BC324A1EC6CQ38815503-C0244B36-D8AC-4BFA-9497-3471ABE3E4AAQ38827338-3E719BCD-70FC-4171-A932-0986E7BEB938Q38855941-F842BB2C-225C-48F2-991B-064DC467FCF8Q38967994-23D0D638-B07F-4CBB-9437-E0ACAC8E36ABQ39051498-E24C6ACE-FE58-4B9C-AA11-E9870D7A795AQ41450711-A85A3D5B-2BAC-4A7D-8FA4-C21B4238E7D4Q41735109-B3DE69AD-67B3-4C2A-875C-0BF218BDD900Q41742863-2A57195B-3C3B-4288-9CD3-2BFB88785D57
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
J D Horowitz
@en
J D Horowitz
@nl
type
label
J D Horowitz
@en
J D Horowitz
@nl
prefLabel
J D Horowitz
@en
J D Horowitz
@nl
P106
P31
P496
0000-0001-6883-0703